In France, on newly acquired land located 7 km from the existing site in Riom north of Clermont-Ferrand in Auvergne, construction have begun in January 2021 with a new, state-of-the-art facility dedicated to custom development and manufacturing of parenteral drug products.
This new state-of-the-art facility will allow for larger capacities to supply our customers with clinical batches for phase III clinical trials and small-scale for commercial. The handling of complex formulations will include a large range of APIs from biologics to highly potent compounds.
Operations will commence during Q1 of 2023.
Line 1 – liquid & lyophilized form Vials | Line 2 – Fill & Finish Vials, Prefilled Syringes and Cartridges | ||
Formulation | Up to 400 Litres tank | ||
Isolator | ![]() | ||
Filling Line | ![]() | ||
Lyophiliser | ![]() | ||
Batch Size | 30k units of 2R – up to 45k | 3.6k units per hour | |
Formats | Vials from 2 to 100ml | Vials from 2 to 100ml PFS 1 to 10ml (option) Cartridges (option) | |
API Categories | Full containment - From Cat 1 to Cat 4+ | ||
Special Features | Low temperature - Inert atmosphere - Viscous products - Aseptic formulation - Minimised losses |
If you would like to keep up with the progress of the site construction and look for more information, please visit our Knowledge Centre.
CARBOGEN AMCIS is a leading service provider, offering a portfolio of drug development and commercialization services to the pharmaceutical and biopharmaceutical industries at all stages of drug development. Our integrated services for Drug Substances (DS) and Drug Products (DP) provide innovative solutions to support timely and safe drug development.